Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda [FOX Business Network]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: FOX Business Network
A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence or death in melanoma patients was cut by about half when combined with Merck's Keytruda, Moderna CEO Stéphane Bancel told FOX Business Wednesday. "The results are really exciting," Bancel told FOX Business' " Mornings with Maria "We saw a recurrence-free survival, meaning people [are] not dying from the disease or getting the disease coming back. At five years, we saw 50% improvement versus people getting Keytruda [alone], Merck's blockbuster medicine, which has saved so many lives. "As you see, this is very meaningful for patients, and we are very excited because this year we should get the Phase 3 study result for that medicine and, hopefully, if it's positive, we should be able to file very quickly with the FDA to get this to the American people to save them from their disease
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Perlmutter-backed Eikon Therapeutics raises $381.2 million in IPO [Yahoo! Finance]Yahoo! Finance
- Jim Cramer on Merck & Co.: “This Is One of My Favorite Pharmaceutical Stocks” [Yahoo! Finance]Yahoo! Finance
- Where is Merck & Co. (MRK) Headed According to Wall Street? [Yahoo! Finance]Yahoo! Finance
- Merck & Co., Inc. (NYSE:MRK) had its price target raised by analysts at Citigroup Inc. from $115.00 to $120.00. They now have a "neutral" rating on the stock.MarketBeat
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- 2/4/26 - Form 144
- MRK's page on the SEC website